Results 51 to 60 of about 28,652 (194)
Rivaroxaban-induced hemorrhage associated with ABCB1 genetic defect
Frontiers in Pharmacology, 2016 We report a patient who presented a non-ST segment elevation myocardial infarction in the context of severe normocytic hypochromic anemia related to gastrointestinal bleeding, three months after switching anticoagulant from the vitamin K antagonist ...
Kuntheavy Ing Lorenzini +4 more
doaj +1 more source
Case report: Severe hepatopathy following rivaroxaban administration in a dog
Frontiers in Veterinary ScienceRivaroxaban, a specific factor Xa inhibitor and commonly utilized anticoagulant, has been known to cause hepatotoxicity and liver failure in humans. Although rivaroxaban is frequently used in veterinary medicine, hepatotoxicity has not been previously ...
Allison P. Mosichuk +5 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016 BackgroundVenous thromboembolism, including deep vein thrombosis and pulmonary embolism, results in a substantial healthcare system burden. This retrospective observational study compared hospital length of stay (LOS) and hospitalization costs for ...
Jay M. Margolis +7 more
doaj +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2020 Direct oral anticoagulants, such as apixaban and rivaroxaban, are important for the treatment and prophylaxis of venous thromboembolism and to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Yukio Otsuka +3 more
doaj +1 more source
RIVAROXABAN USE IN THE TREATMENT OF PATIENTS WITH DEEP VEIN THROMBOSIS OR PULMONARY EMBOLISM
Атеротромбоз, 2020 This article contains information on the possibilities of using rivaroxaban and other non-vitamin K-associated oral anticoagulants (novel oral anticoagulant (NOAC)) in patients with pulmonary embolism (PE) in both acute and later stages of the disease ...
A. D. Erlikh
doaj +1 more source
Pharmacodynamic and pharmacokinetic basics of rivaroxaban [PDF]
Fundamental & Clinical Pharmacology, 2011 AbstractRivaroxaban, an oral, direct factor Xa inhibitor, is a small molecule drug capable of inhibiting not only free factor Xa with high selectivity but also prothrombinase‐bound and clot‐associated factor Xa in a concentration‐dependent manner. Clinical studies have demonstrated predictable anticoagulation and confirmed dose‐proportional effects for
openaire +2 more sources
TH Open, 2018 Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa. Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and activated partial thromboplastin time.
Paul Y. Kim +7 more
doaj +1 more source
Rivaroxaban-Induced Hypersensitivity Syndrome
The Canadian Journal of Hospital Pharmacy, 2017 -
Arnaud Canneva +3 more
openaire +3 more sources
Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
Therapeutics and Clinical Risk Management, 2014 Alexander GG Turpie Department of Medicine, McMaster University, Hamilton, ONT, Canada Abstract: Atrial fibrillation (AF) is the most common cardiac arrhythmia in the developed world and is associated with a fivefold increase in the risk of stroke ...
Turpie AGG
doaj
Frontiers in Cardiovascular MedicineObjectiveRivaroxaban and dabigatran are approved to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF). However, the clinical benefits of rivaroxaban and dabigatran in people with high bleeding risk are unclear.MethodsA ...
Penghui Liu
doaj +1 more source